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A Clinical Evaluation of American Brachytherapy
Society Consensus Guideline for Bulky Vaginal Mass
in Gynecological Cancer
Keiko Nemoto Murofushi, MD,*Þ Nozomi Kitamura, MS,* Yasuo Yoshioka, MD, PhD,*
Minako Sumi, MD, PhD,* Hitoshi Ishikawa, MD, PhD,Þ Masahiko Oguchi, MD, PhD,*
and Hideyuki Sakurai, MD, PhDÞ
Objectives: American Brachytherapy Society (ABS)-recommended interstitial brachy-
therapy (IBT) should be considered for bulky vaginal tumor thicker than 5 mm. The aim of
this study was to evaluate the ABS consensus guideline for patients with severe vaginal
invasion based on our long-term follow-up results.
Methods/Materials: The study included 7 patients with vaginal cancer and 14 patients with
cervical cancer invading to the lower vagina. Based on prebrachytherapy magnetic resonance
imaging findings, patients received intracavitary brachytherapy (ICT) for vaginal tumors 5mm
or less or IBT for vaginal tumors less than 5mm.Nine patients received ICTand the remaining
12 patients received IBT. For dosimetric comparison, an experimental recalculation as the
virtual IBT for patients actually treated by ICT, and vice versa, was performed.
Results: The 5-year local control rate for all tumors was 89.4%. No differences in local
control between ICT- and IBT-treated groups were observed (P = 0.21). One patient ex-
perienced a grade 3 rectal complication. There were no significant differences in the CTV
D90 and rectum D2cc between the 2 groups (P = 0.13 and 0.39, respectively). In the do-
simetric study of ICT-treated patients, neither the actual ICT plans nor the experimental IBT
plans exceeded the limited dose for organs at risk, which were recommended in the guideline
published from the ABS. In the IBT-treated patients, D2cc for bladder and rectum of the
experimental ICT plans was significantly higher than for the actual IBT plans (P G 0.001 and
G0.001, respectively), and 11 experimental ICT plans (92%) exceeded the limited dose for
bladder and/or rectum D2cc.
Conclusions: Tumor control and toxicity after selected brachytherapy according to vaginal
tumor thickness were satisfactory; IBT instead of ICT is recommended for patients with
vaginal tumor thickness greater than 5 mm to maintain bladder and/or rectum D2cc.
Key Words: Cervical cancer with severe vaginal invasion, Vaginal cancer, Dose-volume
histogram parameter, Image-guided brachytherapy
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B rachytherapy as a dose escalation method improves sur-vival in patients undergoing definitive radiotherapy for
cervical cancer,1,2 and appropriate applicators for brachyther-
apy should be selected to adapt to the shape and extent of the
tumor.3 Intracavitary brachytherapy (ICT) with the tandem and
cylinder applicators is mostly used for FIGO IIIA cervical
cancer and vaginal cancer to irradiate the entire vagina. In the
American Brachytherapy Society (ABS) guideline, however,
for avaginal tumor thicker than5mm, interstitial brachytherapy
(IBT) is recommended.4
Image-guided adaptive brachytherapy (IGABT) im-
proved pelvic control and severe late complications, compared
with conventional brachytherapy.5,6 However, few previous
reports evaluated the advantage on dose volume histogram
(DVH) parameters of selected brachytherapy based on the
vaginal tumor thickness.
The aim of this study was to evaluate the ABS con-
sensus guideline when administering the treatments, ICT or
IBT, according to vaginal tumor thickness measured by using
magnetic resonance imaging (MRI) just before brachythera-
py. We also report DVH parameters in ICT and IBT for this
patient category using computed tomography (CT)-based
treatment planning.
MATERIALS AND METHODS
Characteristics of the Patients
We analyzed patients with vaginal cancers thicker than
5 mm, and patients with cervical cancer with the lower half of
vaginal invasion thicker than 5 mm. Vaginal invasion was
measured byMRI obtained just before brachytherapy. Between
July 2010 and June 2013, 21 of 178 patients treated with de-
finitive radiotherapy for cervical cancer and vaginal cancer
were eligible for this study. The primary cancers were cervical
cancer in 14 patients and vaginal cancer in 7 patients. Table 1
shows the details of the patients’ characteristics. This studywas
approved by the ethical review committee at our institution.
Radiotherapy
External beam radiotherapy (EBRT) was delivered by
the three-dimensional (3D)-conformal technique with a linear
accelerator (Clinac IX; VarianMedical System, Palo Alto, CA)
using a 15MVphoton beam. For patients treated by ICT, whole
pelvic EBRTwas initially administered at 30.6 to 39.6 Gy in
17 to 22 fractionswith the 4-field technique, and a further 10.8
to 19.8 Gy in 6 to 11 fractions were irradiated by EBRTwith a
4-cm wide midline block (MB) and the anterior-posterior/
posterior-anterior technique. For patients treated using IBT, an
MBwas inserted along the 50% isodose line, as determined by
IBT planning. Within 7 days before brachytherapy, all patients
underwent MRI.
The first high dose rate-ICT or IBT was performed
within 7 days afterMB insertion. Brachytherapywas performed
using an iridium 192 (192Ir) remote after loading system
(MicroSelectron HDRTM; Nucletron, Veenendaal, the
Netherlands). Brachytherapy planningwas based onCTimages
of 2-mm slice thickness, and calculated using PLATO ver3
(Nucletron) from July 2010 to October 2011 and Oncentra v4.0
(Nucletron) from November 2011 to June 2013. The clinical
target volume (CTV) included the macroscopic residual tumor
(ie, high T2-weighted imaging [T2WI] area onMRI just before
brachytherapy), the entire cervix, and the entirevagina.The ICT
with tandem and cylinder applicators was administered once
weekly to achieve a total dose of 20 to 24 Gy in 4 fractions
prescribed at point A and a depth of 5 mm from the surface of
the vaginal mucosa. The source dwell patternswere determined
using the Manchester system and modified to deliver the pre-
scribed dose to the CTVand to adjust the dose to the organs at
risk (OAR). The Martinez Universal Perineal Interstitial Tem-
platewasused in IBT to deliver a total dose of 24 to 42Gy in4 to
7 fractions over 2 to 4 days to the CTV D90.
Magnetic Resonance Imaging Protocol
A 3.0-T superconductive scanner was used for the MRI
examinations. Transaxial T1-weighted imaging [T1WI] se-
quences (ie, repetition time [TR], 300Y600 ms; echo time
[TE], 10Y20 ms) were obtained with a 5-mm slice thickness,
1.0-mm section gap, and 384  256 matrix size, and the
transaxial T2-weighted sequences (ie, TR, 2500Y5000 ms;
TE, 100Y110 ms) were obtained with a 5-mm slice thickness,
1.0-mm section gap, and 448  288 matrix size. Sagittal T2-
weight images (ie, TR, 3000Y5000ms; TE, 100Y120ms) were
obtained with a 5-mm slice thickness, 1.0-mm section gap,
and 416  288 matrix size.
Selection of the Type of Brachytherapy
A high-T2WI area indicated the vaginal tumor. The
median vaginal tumor thickness by MRI at the stance of the
TABLE 1. Patient and tumor characteristics
Characteristics n
Age, median (range), y 60 (34Y78)
Primary cancer
Cervical cancer (n =14) FIGO IIIA 5
Vaginal cancer (n = 7) IIIB 8
IVA 1
I 1
II 6
Vaginal tumor
site (n = 21)
Upper 2/3 8
Lower 1/3 1
Entire vagina 12
Lymph node
metastasis (n = 21)
Yes 16
No 5
Histology (n = 21) Squamous cell
carcinoma
18
Other 3
Vaginal tumor
thickness
Pretreatment Median, 20 mm
(10Y40 mm)
Prebrachytherapy Median, 8 mm
(0Y33 mm)
FIGO indicates International Federation of Gynecologists and
Obstetricians.
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treatment was 20mm (range, 10Y40mm). The median vaginal
tumor thickness by MRI just before brachytherapy was 8 mm
(range, 0Y33 mm). Selection of the type of brachytherapy was
based on ABS guideline.4 The ICT was principally used for
patients with a vaginal tumor thickness of 5 mm or less on
MRI just before brachytherapy. The IBTwas used for patients
with a vaginal tumor thickness more than 5 mm. Actually, 9
patients were treated by using ICT and 12 patients using IBT.
On MRI just before brachytherapy, as a result, the median
vaginal tumor thickness was 5 mm (range, 0Y8 mm) for 9
patients treated by ICT and 14 mm (range, 6Y33 mm) for 12
patients treated by IBT.
In our institution, IBTwas principally used not only for
vaginal tumor thicker than 5 mm, but also for bulky cervical
tumor and tumor with severe parametrial invasion. In this
study, none of the 9 patients treated with ICT had bulky
cervical tumor or tumor with severe parametrial invasion at
the time of the first brachytherapy.
Chemotherapy
A weekly regimen of TP including paclitaxel (PT;
50 mg/m2) plus cisplatin (CDDP; 30 mg/m2) was principally
administered during the radiotherapy period. Weekly CDDP
at a dose of 40 mg/m2 was used for patients aged 70 years or
older or for patients who did not want alopecia caused by
paclitaxel. Concurrent chemoradiotherapywas not performed
in patients with stage I vaginal cancer, with insufficient renal
function, or aged 75 years or older. Four patients ultimately
received radiotherapy alone. Seventeen patients received
concurrent chemoradiotherapy, and 13 of these patients re-
ceived weekly TP.
Dosimetric Study
For dosimetric comparisons, we performed an experi-
mental recalculation as the virtual IBT for patientswho actually
been treated by ICTand a virtual ICT for patients who actually
been treated by IBT. In particular, for IBT-treated patients, the
experimental ICTplans involved the use of tandemand cylinder
applicators without interstitial needles in the planning CT. For
ICT-treated patients, the experimental IBT plans involved the
virtual insertion of needles. Experimental plans were created
that obtained the same CTV D90 as the actual plans, and the
doses to OAR were compared (Fig. 1).
Two patients who underwent the actual ICT were not
used for this dosimetric study. One patient refused IBT, even
though her vaginal tumor thickness was 8 mm. The other
patient had internal iliac arterial invasion, which was difficult
to be treated by IBT, although the tumor thickness was beyond
5 mm; she was treated by ICT and an EBRT boost to the right
parametrium using the intensity-modulated radiotherapy
technique of administering a dose of 20 Gy in 10 fractions.
Follow up
Treatment responses, based on the Response Evaluation
Criteria in Solid Tumors (RECIST) criteria, were assessed at
2 to 3 months after the completion of radiotherapy usingMRI.
Every 2 to 6 months for 5 years, patients were followed with
cytology, blood tests, and imaging. The median follow-up
duration was 58.9 months (range, 20.9Y80.1 months).
Statistical Analysis
For the dose summation of brachytherapy plus EBRT
before the insertion of the MB, the equivalent dose in 2 Gy
FIGURE 1. Dose distribution curves of actual brachytherapy plan and the experimental brachytherapy plan (the red
line indicates the prescribed dose). The dose distribution curves of the actual IBT (A), experimental ICT (B), actual ICT
(C), and experimental IBT (D).
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fractions (EQD2) was calculated, based on the linear-quadratic
(LQ)model.7 The tumor dosewas calculated using an>/A ratio
of 10 Gy. For calculating the dose-volume parameters of the
OAR (ie, D2.0 cc), the >/A ratio was assumed to be 3 Gy.
The 5-years rates of overall survival (OS), disease-free
survival, and local control (LC) were estimated using the
Kaplan-Meier method. Differences in the outcomes were
compared using the log-rank test. Late adverse events were
graded based on the National Cancer Institute’s Common
Terminology Criteria for Adverse Events, version 4.0. The W2
test and the Student t test were used to compare incidence of
adverse events and DVH data, respectively. The differences in
CTV D90 and doses to organs at risk between the actual IBT
plans and the experimental ICT and between the actual ICT
plans and the experimental IBT were also examined by the
Student t test. The paired t test was used to compare total EQD2
of the CTVD90 and the OARs between the actual IBT plan and
the experimental ICT plan and between the actual ICT plan and
the experimental IBT plan. Statistical significance was at P G
0.05. Statistical analyses were performed by using the SPSS
Base System software program (SPSS, Chicago, IL).
RESULTS
Complete response was obtained from all patients. The
5-year OS rates for all patients, ICT-treated patients, and IBT-
treated patients were 85.2%, 88.9% and 81.8%, respectively
(P = 0.54 for ICT vs IBT) (Fig. 2a). The 5-year disease-free
survival and LC rates for all patients, ICT-treated patients, and
IBT-treated patients were 80.7% and 89.4%, 88.9% and 100%,
and 74.1% and 81.5%, respectively (P = 0.47 and P = 0.21)
(Fig. 2b). At the time of the analysis, local recurrence was
observed in 2 patients who were treated with IBT. In these
patients, 1 had local recurrence at the peripheral external orifice
of the urethra (outside the irradiated field), whereas local re-
currence at the cervix (within the irradiated field) was observed
in another patient with a large tumor with poor response.
Table 2 lists the late adverse rectal events. Radiation
proctitis (RP) developed in 5 (23.8%) patients. Among them,
grade 3 RP was observed in 1 patient treated with IBT, and
hyperbaric oxygen therapy was required. There were no
significant differences in incidence of RP between ICT and
IBT groups (P = 0.45).
The mean EQD2 of the CTVD90 was 67.2 T 5.8 Gy for
all patients. There was no significant difference in the CTV
D90 between ICT- and IBT-patients (P = 0.13) (Fig. 3). There
were also no significant differences in the actual D2cc for the
sigmoid and rectum between the ICT- and IBT-treated pa-
tients (P = 0.13 and 0.39, respectively), although the bladder
D2cc (66.4 T 9.8 Gy) in the IBT-treated patients was signif-
icantly lower than that (78.8 T 10.1 Gy) in the ICT-treated
patients (P = 0.04).
In dosimetric study, the EQD2 of D2cc for bladder,
rectum, and sigmoid of the experimental ICT plans was
significantly higher than those of the actual plans in the IBT-
treated patients (Fig. 4). Similarly, the EQD2 of D2cc for
bladder and rectum of the experimental IBT plans was sig-
nificantly lower than those of the actual plans in the ICT-
treated patients, (P = 0.001 and 0.006, respectively).
When each CTVD90 of the experimental plan was set to
almost equal to actual plan, individual data of D2cc for the
OARs were plotted in Figure 4. Although D2cc of the bladder
and rectum of ICT plans was significantly reduced by use of
IBT in both ICT-treated and IBT-treated patients, the differences
between the actual IBTand the experimental ICT plans in IBT-
treated patients were larger than those between the actual ICT
and the experimental IBT plans in ICT-treated patients.
In the ICT-treated patients, the EQD2 of D2cc for all
OARs of both the actual ICT plans and the experimental IBT
plans did not exceed the limited doses determined by the ABS
consensus guideline; bladder D2cc less than EQD2 90 Gy,
and rectum and sigmoid D2cc less than EQD2 75 Gy (3). In
the IBT-treated patients, rectum D2cc in 1 actual IBT plan
(8%) exceeded 75 Gy (Fig. 3). However, bladder D2cc and/or
rectum D2cc in 11 experimental ICT plans (94%) were higher
than the limited dose.
DISCUSSION
Frank et al8 obtained excellent pelvic control after ad-
ministering definitive radiotherapy without IGABT to 143
patients with vaginal stage I and II cancers but recommended a
tailored radiotherapy using EBRT, ICT, or IBT based on tumor
size, site, and circumferential location. Manuel et al9 showed
that image-based IBT significantly improved LC compared
with nonYimage-based IBT. Recent studies reported that the
FIGURE 2. The Kaplan-Meier curves of overall survival (A) and pelvic recurrence-free survival (B).
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sufficient irradiation doses to CTV using IGABT are very
important to control advanced vaginal tumor, but the indication
to use IBT remains unknown. Furthermore, it is also unclear
whether improved DVH parameters by selected brachytherapy
according to vaginal tumor thickness make better tumor
control or not.9Y11 In the ABS consensus guideline, IBT is
recommended for bulky vaginal cancers thicker than 5 mm.4
The present study evaluated the clinical outcomes for cervical
cancer patients who required irradiation of the entire vagina.
According to vaginal tumor thickness assessed byMRI images
obtained just before brachytherapy, we selected IBT in case of
tumor thickness beyond 5mm.As results, a total EQD2 dose of
65 Gy for mean CTV D90 was delivered for all patient, and no
significant difference in the mean CTV D90 between ICT- and
IBT-treated patients was observed (P = 0.13) (Fig. 3), and se-
lected brachytherapy yielded good 3-year OS and LC rates for
both IBTand ICT group without any differences (P = 0.54 and
0.47, respectively). Grade 3 RP was observed in 1 patient
treated with IBT (Table 2). There was no significant difference
in incidence of RP between ICT and IBT groups (P = 0.45).
Although the incidence of RP tends to increase in patients who
required irradiation for the entire vagina, in this study, the in-
cident rate of severe RP was acceptable in patients treated with
both ICT and IBT.
Concurrent chemoradiotherapy (CCRT), including
weekly CDDP has an important role in the definitive standard
treatment for locally advanced cervical cancer patients.12,13
However, it has been reported that PT increased the radiation
sensitivity of squamous cell carcinoma in vitro, whereas the
combination of TP caused synergistic effects.14,15 In Japan,
phase I study of CCRT recommended aweekly dose of CDDP
30 mg/m2 and PT 50 mg/m2.16 The Japan Clinical Cancer
Research Organization GY-01 trial was a multicenter phase II
prospective study, aimed at evaluating the efficacy of CCRT
including weekly TP, as well as ICT, delivering a prescription
dose to point A for stage III to IVA cervical cancer.17 The 2-year
cumulative pelvic disease progression-free rate was 89.6%. On
the other hand, in Japanese Gynecologic Oncology Group
1066, which evaluated the efficacy of CCRT including weekly
CDDP (40 mg/m2) and ICT, delivering a prescription dose to
point A for stage III to IVA cervical cancer, the 2-year pelvic
disease progression-free rate was 73%.13 In Japan Clinical
Cancer Research Organization GY-01, 60 of 68 patients (88%)
received chemotherapy for 5 cycles or more, whereas planned
radiotherapy was completed in 63 patients (93%).17 The inci-
dence of grade 3 or more leukopeniawas 54.4%, and tended to
be less, compared with that (83%) in Japanese retrospective
study including triweekly CDDP.18 The CCRT, including
weeklyTP, is not a standard treatment; however, it demonstrated
favorable antitumor activity and acceptable adverse effects in
Japanese clinical trials.17
Dimopoulos et al reported that the LC rate was 92% for
patients with advanced vaginal cancer treated by IGABT at
TABLE 2. Late rectal toxicity
All ICT IBT
RP Grade 0 16 (76.2%) 6 (66.7%) 10 (83.4%)
1 2 (9.5%) 2 (22.2%) 0 (0%)
2 2 (9.5%) 1 (11.1%) 1 (8.3%)
3 1 (4.8%) 0 (0%) 1 (8.3%)
Q4 0 (0%) 0 (0%) 0 (0%)
Hematuria Grade 0 21 (100%) 9 (100%) 12 (100%)
FIGURE 3. EQD2 of the CTVD90 (A) and organs at risk [ie, bladder D2.0 cc (B), sigmoidD2.0 cc (C), and rectumD2.0
cc (D)] in the actual and experimental plans.
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the mean total dose of 86 Gy to 90% volume for CTV.9 The
Groupe Europe´en de Curiethe´rapie and the European Society
for Radiotherapy and Oncology (GECYESTRO) and ABS
recommend delivery of a cumulative dose of approximately
80 to 90 Gy for the target volume.3,19 However, the protocols
in Japanese studies traditionally have used lower doses in a
shorter overall treatment time, compared with the protocols in
these countries.20,21 Actually, Japanese Gynecologic Oncol-
ogy Group 1066 demonstrated comparable outcomes of
concurrent chemoradiotherapy delivering an EQD2 of 62 to
65 Gy to point A for stage III/IVA cervical cancer to results
from studies at the United States and European countries.13 In
this study, at the time of the analysis, 2 patients had local
recurrence while receiving a total EQD2 dose of 65 Gy for
mean CTV D90; then, 1 patient, who experienced local re-
currence within the irradiated field, had a large tumor with
poor response. In future, we should try to escalate the dose to
the CTV for large tumors with poor response while reducing
the dose to OARs by using IBT.
In this study, ICTwith tandem and cylinder applicators
principally administered a prescription to point A rather than
to an MRI-defined volume, and the source dwell patterns
were modified to deliver the prescribed dose to the CTV and
to adjust the dose to OAR. The reason we conducted this
treatment planning procedure is that we thought it could make
the dose distribution for each patient more uniform and avoid
unexpected high dosage area in the vaginal mucosa.
If the tumor invades to the lower vagina, ICT with
tandem and cylinder applicators is more useful to irradiate the
entire vagina rather than ICT with tandem and ovoid appli-
cators, but it is difficult to deliver a sufficient dose to the
parametrium while sparing OARs. In our institution, IBTwas
selected if the patients had at least 1 tumor character listed as
follows: 1) vaginal tumor thicker than 5 mm, 2) bulky cervical
tumor, and 3) tumor with severe parametrial invasion. In this
study, none of the 9 thinvaginal tumor patients treatedwith ICT
had bulky cervical tumor or tumor with severe parametrial
invasion. If patients with vaginal tumor 5 mm thick or less had
simultaneously bulky cervical tumor or tumor with severe
parametrial invasion, IBT is selected to deliver a sufficient dose
to CTV.
To safely perform brachytherapy for cervical cancer, the
GEC-ESTRO and ABS recommend calculating the dose of
D0.1cc, D1cc, and D2cc to OAR such as the bladder, sigmoid,
and rectum.3,22 In ABS guideline, the D2cc for the rectum and
sigmoid should be reduced to less than 70 to 75 Gy, and the
D2cc for the bladder should be less than 90Gy.3,23 Results
from the EMBRACE study showed that severe rectal toxic-
ities, with higher frequencies, occurred with D2cc value of
75 Gy or more.24 In this study, both ICT- and IBT-treated pa-
tients received the rectum D2cc value of approximately 60 Gy,
and there was no significant difference between 2 treatment
groups. On the other hand, the bladder D2cc in the ICT-treated
patients was significantly higher than that in the IBT-treated
patients (P = 0.04). There were, however, no differences in
complications in the urinary systembecause no patient received
90Gyormore for the bladderD2cc in both ICT- and IBT-treated
patients. Hence, selected brachytherapy based on the threshold
of 5mm for vaginal tumor thickness could deliver the sufficient
doses to CTV while under the limited dose of OARs, such as
bladder, sigmoid, and rectum.
In this study, a dosimetric evaluation as thevirtual IBT for
patients actually treated by ICT, and vice versa, was performed
to assess whether our selection criteria of brachytherapy type
FIGURE 4. The comparison between the actual brachytherapy plan and the simulated brachytherapy plan of the
dose-volume histogram parameters for CTV D90 (A) and OAR [ie, bladder D2.0 cc (B), sigmoid D2.0 cc (C), and
rectum D2.0 cc (D)].
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was appropriate or not. In the IBT-treated patients with their
vaginal tumors thicker than5mm, irradiated doses and volumes
of bladder, rectum, and sigmoid colon in the experimental ICT
planswere higher than those in the actual IBT plans (P G 0.001,
0.002, and G0.001, respectively) (Fig. 4). Among them, the
mean D2cc for bladder and rectum in the experimental plans
was extremely high (143.0 Gy and 98.1 Gy, respectively), and
11 of 12 plans (92%) exceeded at least any one of the limited
doses for bladder D2cc, rectum D2cc, and sigmoid colon D2cc
(Fig. 3). Therefore, many severe complications at the bladder
and rectum may occur if ICT is selected for patients with their
vaginal tumor thickness beyond 5 mm.
On the other hand, in the ICT-treated patients, who had
the vaginal tumor measuring 5 mm or less, D2cc for bladder
and rectum of the actual ICT plans was also higher than those
of the experimental IBT plans (P = 0.001 and 0.006, re-
spectively). However, the D2cc for bladder, rectum, and
sigmoid colon was acceptable in both of the actual ICT plans
and the experimental IBT plans. The IBT has a small ad-
vantage for patients with vaginal tumor thickness less than
5 mm because no actual ICT plans exceeded the limited dose
of bladder D2cc according to the ABS consensus guideline.
Kirchheiner et al reported that brachytherapy with 2 fractions
in 1 application under spinal/epidural anesthesia caused post-
traumatic stress disorder, which occurred in 41% of patients
3 months after treatment.25 The IBT generally carries a severe
mental and physical burden on the patient compared with ICT.
Taking the obtained results and the mental and physical burden
on the patients into consideration, there was almost no benefit
on most ICT-treated patients if they had received more invasive
IBT. Based on results from dosimetric comparison in this study,
the usefulness of selected brachytherapy for cervical cancer
with vaginal invasion based on the guideline published from the
ABS was confirmed.
The limitation of this study is that it was retrospectively
analyzed and included a small number of patients. Further
prospective study with a large number of patients is necessary
to more accurately evaluate the ABS consensus guideline in
patients with severe vaginal invasion.
CONCLUSIONS
Selected ICT or IBT as an appropriate brachytherapy
method according to prebrachytherapy MRI evaluation of
vaginal tumor thickness based on ABS guidelines have
yielded high LC ratewith low complication rate. In dosimetric
comparison, almost all experimental ICT plans for the IBT-
treated patientswith vaginal tumor thicker than 5mm exceeded
the limited doses of bladder D2cc and/or rectum D2cc. Results
from the present study strongly support brachytherapy selection
according to ABS consensus guidelines for vaginal tumor
treatment, with an improvement seenwith IBT in terms ofOAR
doses for all patients with gross vaginal disease, irrespective of
the thickness.
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